Vaxcyte, Inc. (PCVX)
PCVX Stock Price Chart
Explore Vaxcyte, Inc. interactive price chart. Choose custom timeframes to analyze PCVX price movements and trends.
PCVX Company Profile
Discover essential business fundamentals and corporate details for Vaxcyte, Inc. (PCVX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
12 Jun 2020
Employees
414.00
Website
https://vaxcyte.comCEO
Grant E. Pickering
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
PCVX Financial Timeline
Browse a chronological timeline of Vaxcyte, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 23 Feb 2026
Upcoming earnings on 4 Nov 2025
EPS estimate is -$1.23.
Earnings released on 6 Aug 2025
EPS came in at -$1.22 falling short of the estimated -$1.12 by -8.93%.
Earnings released on 7 May 2025
EPS came in at -$1.04 falling short of the estimated -$1.02 by -1.96%.
Earnings released on 25 Feb 2025
EPS came in at -$1.02 surpassing the estimated -$1.16 by +12.07%.
Earnings released on 5 Nov 2024
EPS came in at -$0.83 surpassing the estimated -$1.10 by +24.55%.
Earnings released on 6 Aug 2024
EPS came in at -$1.10 falling short of the estimated -$0.98 by -12.75%.
Earnings released on 8 May 2024
EPS came in at -$0.85 surpassing the estimated -$1.13 by +24.78%.
Earnings released on 27 Feb 2024
EPS came in at -$1.82 falling short of the estimated -$0.90 by -102.22%, while revenue for the quarter reached $14.45M .
Earnings released on 6 Nov 2023
EPS came in at -$0.91 falling short of the estimated -$0.79 by -15.19%.
Earnings released on 8 Aug 2023
EPS came in at -$0.70 falling short of the estimated -$0.67 by -4.48%.
Earnings released on 8 May 2023
EPS came in at -$0.70 surpassing the estimated -$0.80 by +12.50%.
Earnings released on 27 Feb 2023
EPS came in at -$0.73 surpassing the estimated -$0.84 by +13.10%.
Earnings released on 7 Nov 2022
EPS came in at -$0.93 falling short of the estimated -$0.80 by -16.25%.
Earnings released on 8 Aug 2022
EPS came in at -$0.80 falling short of the estimated -$0.69 by -15.94%.
Earnings released on 9 May 2022
EPS came in at -$0.68 falling short of the estimated -$0.56 by -21.43%.
Earnings released on 28 Feb 2022
EPS came in at -$0.54 falling short of the estimated -$0.46 by -17.39%.
Earnings released on 10 Nov 2021
EPS came in at -$0.51 falling short of the estimated -$0.47 by -8.51%.
Earnings released on 11 Aug 2021
EPS came in at -$0.46 matching the estimated -$0.46.
Earnings released on 11 May 2021
EPS came in at -$0.41 matching the estimated -$0.41.
Earnings released on 29 Mar 2021
EPS came in at -$0.41 surpassing the estimated -$0.48 by +14.58%.
Earnings released on 12 Nov 2020
EPS came in at -$0.41 surpassing the estimated -$0.42 by +2.38%.
PCVX Stock Performance
Access detailed PCVX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.